A CysLT1 and CysLT2 receptor antagonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

BAY u9773

Item No. 70770

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
4-[[(1R,2E,4E,6Z,9Z)-1-[(1S)-4-carboxy-1-hydroxybutyl]-2,4,6,9-pentadecatetraenyl]thio]-benzoic acid
CAS Number
154978-38-8
Molecular Formula
C27H36O5S
Formula Weight
472.6
Purity
≥95%
Formulation (Request formulation change)
A 100 µg/ml solution in ethanol
Solubility(Learn about Variance in Solubility)
DMF: 25 mg/mlDMSO: 25 mg/mlEthanol: 25 mg/mlPBS (pH 7.2): .15 mg/ml
λmax
279 nm
SMILES
CCCCC/C=C\C\C=C/C=C\C=C/[C@@H](Sc1ccc(cc1)C(=O)O)C(O)CCCC(=O)O
InChi Code
InChI=1S/C27H36O5S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-25(24(28)15-14-17-26(29)30)33-23-20-18-22(19-21-23)27(31)32/h6-7,9-13,16,18-21,24-25,28H,2-5,8,14-15,17H2,1H3,(H,29,30)(H,31,32)/b7-6-,10-9-,12-11+,16-13+/t24-,25+/m0/s1
InChi Key
PKJINWOACFYDQN-RBVMPENBSA-N
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    25 µg

    $71

    Add

    50 µg

    $131

    Add

    100 µg

    $248

    Add

    500 µg

    $1,091

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    BAY u9773 is a cysteinyl leukotriene 1 (CysLT1) and CysLT2 receptor antagonist.1 It inhibits contractions induced by leukotriene D4 (LTD4; Item No. 20310) or LTC4 (Item No. 20210) in isolated guinea pig trachea, rat lung, ferret spleen, and sheep bronchus (pA2s = 6.8-7.4). BAY u9773 (0.1 mg/kg) suppresses airway hypersensitivity and bronchoalveolar lavage fluid (BALF) eosinophil infiltration in a guinea pig model of ovalbumin-induced asthma.2 It also increases the latency to generalized seizures and decreases the EEG amplitude in a mouse model of seizures induced by pentylenetetrazol (PTZ; Item No. 18682).3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Tudhope, S.R., Cuthbert, N.J., Abram, T.S., et al. BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes. Eur. J. Pharmacol. 264, 317-323 (1994).

    2. Muraki, M., Imbe, S., Santo, H., et al. Effects of a cysteinyl leukotriene dual ½ receptor antagonist on antigen-induced airway hypersensitivity and airway inflammation in a guinea pig asthma model. Int. Arch. Allergy Appl. Immunol. 155(Suppl. 1), 90-95 (2011).

    3. Lenz, Q.F., Arroyo, D.S., Temp, F.R., et al. Cysteinyl leukotriene receptor (CysLT) antagonists decrease pentylenetetrazol-induced seizures and blood-brain barrier dysfunction. Neuroscience 277, 859-871 (2014).

    Product Citations

    Ni, N.C., Yan, D., Ballantyne, L.L., et al. A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice. J. Pharmacol. Exp. Ther. 339(3), 768-778 (2011).